Daratumumab for late antibody-mediated rejection in kidney transplant
Treatments studied
Part of Immune system & allergy, Kidney & urinary clinical trials.
This trial tests whether daratumumab can help treat a type of rejection that happens more than a year after a kidney transplant. It may be an option for people who have biopsy-proven antibody-mediated rejection and new donor-specific antibodies.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have received a kidney transplant (first or later one)
- You were diagnosed with antibody-mediated rejection more than 12 months after your transplant
- A biopsy has confirmed this type of rejection
- You have new donor-specific antibodies (DSA)
- You do not have an active infection or serious health issues that could interfere
- You have not been treated with daratumumab before
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if daratumumab can help people with a kidney condition called MGRS, where abnormal proteins damage the kidneys. The goal is to see if the drug can reduce protein in the urine and protect kidney function.
This Phase 2 trial tests daratumumab to reduce your body’s immune reaction (HLA antibodies) before a heart or heart-and-kidney transplant. It may help lower the risk of immediate, severe rejection in people who already have high antibody levels.
This study tests a new combination of drugs (an antibody called CD38 mAb plus azathioprine) to treat a type of chronic rejection that can happen months or years after a kidney transplant. The goal is to see if it can help stabilize or improve kidney function and prevent further damage.
This trial tests whether belatacept can help prevent damage in kidney transplant recipients who develop new antibodies against their donor kidney. It is for people whose kidney function is still stable, which may allow treatment to slow or stop antibody-related injury.
This trial tests a drug called daratumumab for people with aplastic anemia that hasn't improved with standard treatments. The goal is to see if it can help your bone marrow make more blood cells and improve your blood counts.
This study tests a new medicine called mezagitamab for people whose kidney transplant is being rejected by their immune system (a condition called antibody-mediated rejection). The goal is to see if it can help stop the rejection and protect the transplanted kidney.
Hear when a new Kidney Tansplant trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.